NewCo News: Stealth Moves Mitochondrial Candidate into Phase II Trials
By Marie Powers
Friday, October 7, 2011
Despite its moniker, privately held Stealth Peptides Inc. is poised to make a name for itself in the development of mitochondrial-targeted therapies, potentially addressing cardiovascular, renal, ophthalmologic, neurologic and metabolic indications.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.